Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Introduction: Although therapeutic choices for patients with chronic lymphocytic leukemia (CLL) were once limited, treatment of this disease has vastly improved in the last decades.Patients and methods: Consecutive CLL patients diagnosed in a single institution were analyzed. Treatment was withheld in persons with CLL Rai stage 0 or 1, until progression and in persons with stages 2-4, with a negative expression of ZAP-70 until progression. Between 1983 and 1991, patients were give chlorambucil and prednisone (CP); after 1991 fludarabine and cyclophosphamide (FC) and after 1998, rituximab and FC (FCR).Results: 98 patients with CLL were identified; 49 were followed for >3 months. 21 persons (43%) did not require treatment nor progressed; 14 received CP, 6 FC, 7 FCR and one rituximab. Median overall survival (OS) has not been reached, being above 247 months; median OS for patients given CP was 115 months, for FC above 132 months and for FCR above 136 months (p > 0.5).Conclusion: CLL seems to be less aggressive in Mexican mestizos than in Caucasians; 43% of patients do not need treatment at all.

authors

  • Cruz-Mora, Antonio
  • Murrieta-Alvarez, Iván
  • Olivares-Gazca, Juan Carlos
  • León-Peña, Andrés
  • Cantero-Fortiz, Yahveth
  • García-Navarrete, Yarely Itzayana
  • Sánchez-Valledor, Luisa Fernanda
  • Khalif, Dina
  • Ruiz-Delgado, Guillermo José
  • Ruiz-Argüelles, Guillermo José

publication date

  • January 1, 2020